Comparison of inhaled nitric oxide and aerosolized iloprost in pulmonary hypertension in children with congenital heart surgery

Cardiology Journal

Volumn 19, Issue 4, 2012, Pages 387-394

  Kirbas, Ahmet ^a   Yalcin, Yalim ^a   Tanrikulu, Nursen ^a   Gürer, Onur ^a   Isik, Ömer ^a  

^a Medicana International Istanbul   (Turkey)

Author keywords

Aerosolized iloprost; Nitric oxide; Pulmonary hypertension

Indexed keywords

ILOPROST; NITRIC OXIDE;

AEROSOL; ARTICLE; CARDIOPULMONARY BYPASS; CENTRAL VENOUS PRESSURE; CHILD; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY PRESSURE; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; EXTUBATION; HEART HEMODYNAMICS; HEART OUTPUT MEASUREMENT; HEART RATE; HEART SURGERY; HEMODYNAMIC MONITORING; HUMAN; INFANT; LUNG ARTERY PRESSURE; MORTALITY; PREOPERATIVE PERIOD; PRESCHOOL CHILD; PULMONARY HYPERTENSION; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; AEROSOLS; ANTIHYPERTENSIVE AGENTS; CARDIAC SURGICAL PROCEDURES; CHILD; CHILD, PRESCHOOL; HEART DEFECTS, CONGENITAL; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INFANT; INFANT, NEWBORN; NITRIC OXIDE; TIME FACTORS; TREATMENT OUTCOME; TURKEY; VASODILATOR AGENTS;

EID: 84864033033     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: 10.5603/CJ.2012.0070     Document Type: Article

References (20)

1. Galiè N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J, 2009; 30: 2493-2537.
2. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: A 2-year study. Heart, 2007; 93: 350-354.
3. Voswinckel R, Enke B, Reichenberger F et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: Results from randomized controlled pilot studies. J Am Coll Cardiol, 2006; 48: 1672-1681.
4. Pepke-Zaba J, Gilbert C, Collings L, Brown MC. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest, 2008; 133: 183-189.
5. Russell IA. Con: Intraoperative use of nitric oxide for treatment of pulmonary hypertension in patients with congenital heart disease is not effective. J Cardiothorac Vasc Anesth, 2001; 15: 263-264.
6. Mossad EB. Pro: Intraoperative use of nitric oxide for treatment of pulmonary hypertension in patients with congenital heart disease is effective. J Cardiothorac Vasc Anesth, 2001; 15: 259-262.
7. Fisher CA, Kappa JR, Sinha AK et al. Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E1, on human platelet function. J Lab Clin Med, 1987; 109: 184-190.
8. Limsuwan A, Wanitkul S, Khosithset A, Attanavanich S, Samankatiwat P. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol, 2008; 129: 333-338.
9. Bando K, Turrentine MW, Sharp TG et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg, 1996; 112: 1600-1609.
10. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: A randomised double-blind study. Lancet, 2000; 356: 1464-1469.
11. Day RW, Hawkins JA, McGough EC, Crezeé KL, Orsmond GS. Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease. Ann Thorac Surg, 2000; 69: 1907-1913.
12. Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg, 2002; 124: 628-629.
13. Trachte AL, Lobato EB, Urdaneta F et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg, 2005; 79: 194-197.
14. Knoderer CA, Ebenroth ES, Brown JW. Chronic outpatient sildenafil therapy for pulmonary hypertension in a child after cardiac surgery. Pediatr Cardiol, 2005; 26: 859-861.
15. Loukanov T, Bucsenez D, Springer W et al. Comparison of inhaled nitric oxide with aerosolized iloprost for treatment of pulmonary hypertension in children after cardiopulmonary bypass surgery. Clin Res Cardiol, 2011; 100: 595-602.
16. Palma G, Giordano R, Russolillo V et al. Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery. Tex Heart Inst J, 2011; 38: 238-242.
17. Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest, 2003; 124: 1294-1304.
18. Hirata M, Murad F. Interrelationships of cyclic GMP, inositol phosphates, and calcium. Adv Pharmacol, 1994; 26: 195-216.
19. Zwissler B, Rank N, Jaenicke U et al. Selective pulmonary vasodilation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypass. Anesthesiology, 1995; 82: 1512-1516.
20. Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol, 2000; 35: 176-182.